scholarly journals Loss of renal olfactory receptor 1393 leads to improved glucose homeostasis in a type 1 diabetic mouse model

2021 ◽  
Vol 9 (23) ◽  
Author(s):  
Alexis R. Schiazza ◽  
Elizabeth G. Considine ◽  
Madison Betcher ◽  
Blythe D. Shepard
Keyword(s):  
Mouse Model ◽  
Glucose Homeostasis ◽  
Olfactory Receptor ◽  
Diabetic Mouse

Specific MAPK inhibitors prevent hyperglycemia-induced renal diseases in type 1 diabetic mouse model

2016 ◽  
Vol 419 (1-2) ◽  
pp. 1-9 ◽  
Author(s):  
Zhe Hong ◽  
Zongyuan Hong ◽  
Denglong Wu ◽  
Hezhongrong Nie
Keyword(s):  
Mouse Model ◽  
Diabetic Mouse ◽  
Renal Diseases ◽  
Mapk Inhibitors

scholarly journals Genetic Interactions among Idd3, Idd5.1, Idd5.2, and Idd5.3 Protective Loci in the Nonobese Diabetic Mouse Model of Type 1 Diabetes

2013 ◽  
Vol 190 (7) ◽  
pp. 3109-3120 ◽  
Author(s):  
Xiaotian Lin ◽  
Emma E. Hamilton-Williams ◽  
Daniel B. Rainbow ◽  
Kara M. Hunter ◽  
Yang D. Dai ◽  
...  
Keyword(s):  
Type 1 Diabetes ◽  
Mouse Model ◽  
Diabetic Mouse ◽  
Genetic Interactions ◽  
Nonobese Diabetic Mouse ◽  
Nonobese Diabetic

scholarly journals Baicalin reversal of DNA hypermethylation-associated Klotho suppression ameliorates renal injury in type 1 diabetic mouse model

Cell Cycle ◽  
2020 ◽  
Vol 19 (23) ◽  
pp. 3329-3347
Author(s):  
Xiao-Tan Zhang ◽  
Guang Wang ◽  
Liu-Fang Ye ◽  
Yu Pu ◽  
Run-Tong Li ◽  
...  
Keyword(s):  
Mouse Model ◽  
Renal Injury ◽  
Diabetic Mouse ◽  
Dna Hypermethylation

scholarly journals Thymically-derived Foxp3+ regulatory T cells are the primary regulators of type 1 diabetes in the non-obese diabetic mouse model

PLoS ONE ◽  
2019 ◽  
Vol 14 (10) ◽  
pp. e0217728 ◽  
Author(s):  
Daniel R. Holohan ◽  
Frédéric Van Gool ◽  
Jeffrey A. Bluestone
Keyword(s):  
T Cells ◽  
Type 1 Diabetes ◽  
Regulatory T Cells ◽  
Mouse Model ◽  
Diabetic Mouse

scholarly journals Islet  -Cell Endoplasmic Reticulum Stress Precedes the Onset of Type 1 Diabetes in the Nonobese Diabetic Mouse Model

Diabetes ◽  
2012 ◽  
Vol 61 (4) ◽  
pp. 818-827 ◽  
Author(s):  
S. A. Tersey ◽  
Y. Nishiki ◽  
A. T. Templin ◽  
S. M. Cabrera ◽  
N. D. Stull ◽  
...  
Keyword(s):  
Endoplasmic Reticulum ◽  
Type 1 Diabetes ◽  
Endoplasmic Reticulum Stress ◽  
Mouse Model ◽  
Islet Cell ◽  
Diabetic Mouse ◽  
Nonobese Diabetic Mouse ◽  
Nonobese Diabetic

scholarly journals Dulaglutide Alone and in Combination with Empagliflozin Attenuate Inflammatory Pathways and Microbiome Dysbiosis in a Non-Diabetic Mouse Model of NASH

Biomedicines ◽  
2021 ◽  
Vol 9 (4) ◽  
pp. 353
Author(s):  
Katharina Luise Hupa-Breier ◽  
Janine Dywicki ◽  
Björn Hartleben ◽  
Freya Wellhöner ◽  
Benjamin Heidrich ◽  
...  
Keyword(s):  
Mouse Model ◽  
Glucose Homeostasis ◽  
Diabetic Mouse ◽  
Significant Weight Loss ◽  
High Fat ◽  
Beneficial Effects ◽  
High Fructose ◽  
Patients With Diabetes ◽  
Anti Inflammatory ◽  
Long Acting

Dysregulation of glucose homeostasis plays a major role in the pathogenesis of non-alcoholic steatohepatitis (NASH) as it activates proinflammatory and profibrotic processes. Beneficial effects of antiglycemic treatments such as GLP-1 agonist or SGLT-2 inhibitor on NASH in patients with diabetes have already been investigated. However, their effect on NASH in a non-diabetic setting remains unclear. With this aim, we investigated the effect of long-acting GLP1-agonist dulaglutide and SGLT-2 inhibitor empagliflozin and their combination in a non-diabetic mouse model of NASH. C57BL/6 mice received a high-fat-high-fructose (HFHC) diet with a surplus of cholesterol for 16 weeks. After 12 weeks of diet, mice were treated with either dulaglutide, empagliflozin or their combination. Dulaglutide alone and in combination with empagliflozin led to significant weight loss, improved glucose homeostasis and diminished anti-inflammatory and anti-fibrotic pathways. Combination of dulaglutide and empagliflozin further decreased MoMFLy6CHigh and CD4+Foxp3+ T cells. No beneficial effects for treatment with empagliflozin alone could be shown. While no effect of dulaglutide or its combination with empaglifozin on hepatic steatosis was evident, these data demonstrate distinct anti-inflammatory effects of dulaglutide and their combination with empagliflozin in a non-diabetic background, which could have important implications for further treatment of NASH.

scholarly journals The type 1 diabetes candidate gene Dexi does not affect disease risk in the nonobese diabetic mouse model

2019 ◽  
Vol 21 (1) ◽  
pp. 71-77 ◽  
Author(s):  
Janice M. Nieves-Bonilla ◽  
Badr Kiaf ◽  
Cornelia Schuster ◽  
Stephan Kissler
Keyword(s):  
Type 1 Diabetes ◽  
Mouse Model ◽  
Candidate Gene ◽  
Disease Risk ◽  
Diabetic Mouse ◽  
Nonobese Diabetic Mouse ◽  
Nonobese Diabetic ◽  
Diabetes Candidate Gene

Cardiomyopathy and Diastolic Dysfunction in the Embryo and Neonate of a Type 1 Diabetic Mouse Model

2012 ◽  
Vol 20 (7) ◽  
pp. 781-790 ◽  
Author(s):  
Niamh Corrigan ◽  
Ann Treacy ◽  
Derek P. Brazil ◽  
Fionnuala M. McAuliffe
Keyword(s):  
Mouse Model ◽  
Diastolic Dysfunction ◽  
Diabetic Mouse
Sign in / Sign up

Export Citation Format

Share Document